The pharmacological bases of the antiangiogenic activity of paclitaxel.
about
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaCurrent Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/AngiogenesisLow-Dose Paclitaxel Inhibits Tumor Cell Growth by Regulating Glutaminolysis in Colorectal Carcinoma Cells.Cytotoxic effects of docetaxel as a candidate drug of drug-eluting stent on human umbilical vein endothelial cells and the signaling pathway of cell migration inhibition, adhesion delay and shape changeRamucirumab: successfully targeting angiogenesis in gastric cancer.Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.Remodeling Characteristics and Collagen Distributions of Biologic Scaffold Materials Biopsied From Postmastectomy Breast Reconstruction Sites.The impact of chemotherapy and radiation therapy on the remodeling of acellular dermal matrices in staged, prosthetic breast reconstruction.Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study.Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapyAnti-angiogenic Nanotherapy Inhibits Airway Remodeling and Hyper-responsiveness of Dust Mite Triggered Asthma in the Brown Norway Rat.Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models.Ramucirumab for gastric cancer.Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease.JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system.Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel.A spatiotemporally defined in vitro microenvironment for controllable signal delivery and drug screening.Clinical Development of Anti-mitotic Drugs in Cancer.Electrochemotherapy in the Treatment of Massive, Multisite Breast Cancer Metastasis to the Skin and Subcutaneous Tissue: A Case ReportMechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology.From the lymph nodes to the muscles: an unusual case of refractory familial Mediterranean classic Kaposi sarcoma.Mcl-1 stabilization confers resistance to taxol in human gastric cancer.Role of β-Interferon Inducer (DEAE-Dextran) in Tumorigenesis by VEGF and NOTCH1 Inhibition along with Apoptosis Induction.DCE- and DW-MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer.Pullulan-coated phospholipid and Pluronic F68 complex nanoparticles for carrying IR780 and paclitaxel to treat hepatocellular carcinoma by combining photothermal therapy/photodynamic therapy and chemotherapy.Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells.Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer.RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo.Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
P2860
Q26741530-962172F6-F46B-4800-B6BF-0A70A3952BF6Q28077780-CBD16FC1-0019-4264-825B-8EAC5BA04004Q33634260-40EAC38A-D912-4BD0-9180-0F0288C7EBC1Q33762904-FD527EF3-EA77-4219-831B-117C548D142FQ34616558-E85F5C69-42EF-4D00-91BD-F3DCC945D73BQ34780933-0A664144-6196-4A21-B106-0B87C676F7DBQ35738624-4CF17649-4E04-4E8F-9ED8-FBD987FB2E5BQ35889011-7F3B7AC9-9C62-471B-B17C-B75462726F0BQ36004194-689D23E7-8CA5-43FF-AC01-4E41CFDDD5C3Q36359684-BBDBC716-9D9A-4353-90A0-2D2112872037Q37509823-BD1CFDD8-8F27-47D9-9DB1-61C05C2D0656Q37541992-F9BC2F86-C59D-46C1-8525-32B301576073Q37627010-A117C253-5ECF-4B83-AAAB-C7E4B7D3D52AQ38272318-081AF563-DAC7-4990-85DB-FBA989295972Q38286373-504B4EC8-EFBB-401D-BA86-53FE1B5E2BE5Q38729973-C06D7692-1E37-4A40-8BD5-057506AFB0C6Q38736541-A9456DDD-EC9A-4488-9876-FBF364FDF3E0Q38765403-05A33F93-C467-4C1A-9078-B4913D41A917Q38794776-B1A3FA13-441F-4B0A-84C2-7B3CCD7D4F64Q38922051-21036689-B6FA-4B91-9C27-8DF41727CA88Q38968948-3CCEDF89-FD01-4485-9620-B0C5EF6181EFQ39363642-E4A52BEC-CBEA-43D2-A45F-9879508B24EBQ41635885-B1720382-5461-441D-A0C2-09F2BBCCE50BQ42145728-C9597564-2714-46BC-AB53-675FBAFF9359Q42219101-883B731B-AC8A-4371-90FB-F558622A6857Q43637703-08C692BD-5ACD-45DD-AD2A-EF3ED4743FC0Q47192395-0941374A-C12F-4290-A40F-4D7876A9E85BQ47670339-70723DCE-5854-4217-88AA-EC70859CB49CQ48564875-470DEF58-F491-4487-89DA-C7A1D624A64FQ49747089-017B5A72-11D2-4EFB-8602-AB2A03D8025EQ50675790-0FB244F3-B0EF-41B1-A1F9-42031651C84FQ50955720-6A92468F-4263-4B1F-80A8-5CF48C5EF34BQ58705919-0D7DA624-950F-4BB5-925F-0AF894B6328F
P2860
The pharmacological bases of the antiangiogenic activity of paclitaxel.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The pharmacological bases of the antiangiogenic activity of paclitaxel.
@en
type
label
The pharmacological bases of the antiangiogenic activity of paclitaxel.
@en
prefLabel
The pharmacological bases of the antiangiogenic activity of paclitaxel.
@en
P2093
P2860
P921
P1433
P1476
The pharmacological bases of the antiangiogenic activity of paclitaxel.
@en
P2093
Antonello Di Paolo
Guido Bocci
Romano Danesi
P2860
P2888
P304
P356
10.1007/S10456-013-9334-0
P577
2013-02-07T00:00:00Z
2013-07-01T00:00:00Z